Eli Lilly and Stock Price. Everything You Need To Know About The Eli Lilly and Stock! Eli Lilly and Stock Price. Everything You Need To Know About The Eli Lilly and Stock!


What is Eli Lilly and Stock Price. Everything You Need To Know About The Eli Lilly and Stock!?

Eli Lilly & Co. is a renowned pharmaceutical company headquartered in Indianapolis, Indiana with a global presence in over 120 countries. With a workforce of 35,000 full-time employees, the firm specializes in the discovery, development, manufacturing, and sale of various human pharmaceutical products. The company offers a diverse range of products, including diabetes products such as Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity, oncology products like Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio, and immunology products such as Olumiant, Baricitinib, and Taltz. Additionally, it provides neuroscience products like Cymbalta, Emgality, and Zyprexa, and other therapies such as Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. As a major player in the pharmaceutical industry, the company caters to various market segments, including wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. Investors who want to stay on top of the latest developments can track Eli Lilly & Co.'s share price and market cap. The stock price today, including stocks share price today, is available through various financial news outlets, while premarket trading is also an option for some investors. In conclusion, Eli Lilly & Co. is a leading pharmaceutical company with a strong presence in the global market. Its diverse range of products and customer-focused approach have helped establish its position as a top player in the industry. Investors interested in the company can track its share price, market cap, and other important metrics to make informed investment decisions.


Eli Lilly and Stock Price. Everything You Need To Know About The Eli Lilly and Stock! performance

  • Employees

    35000
  • Company HQ

    Indianapolis
  • Website

    https://www.lilly.com/
  • LLY Asset Type

    Common Stock
  • LLY Market Capitalization

    669.3B
  • Earnings Per Share 5.5
  • Dividends Per Share 4.37
  • Dividend Date 2024-03-08
  • Quarterly Earnings Growth 0.857

How To Invest In Eli Lilly and Company Stock From Malaysia, Thailand, Indonesia & Vietnam

Company Profile: Eli Lilly and Company is a global pharmaceutical company renowned for its innovative approach to drug development and healthcare solutions. With a rich history spanning over a century, Eli Lilly has become a trusted name in the industry, consistently delivering breakthrough medications in various therapeutic areas. Investing in Eli Lilly: If you are a retail investor from Malaysia, Thailand, Indonesia, or Vietnam, interested in investing in Eli Lilly and Company, Zorion offers a user-friendly platform to seamlessly invest in real US stocks. By leveraging our investment insights and recommendations, you can make informed decisions about your investment portfolio. Access educational materials and resources provided by Zorion to expand your investment knowledge and fully understand the potential opportunities offered by Eli Lilly and Company. Start your investment journey with Zorion and gain exposure to one of the leading global pharmaceutical companies.

How To Buy Eli Lilly and Company Stock From Malaysia, Thailand, Indonesia & Vietnam

Company Overview: Eli Lilly and Company is a global pharmaceutical company with a focus on developing and manufacturing innovative healthcare solutions. With a rich history spanning over a century, the company is renowned for its expertise in the areas of neuroscience, endocrinology, oncology, and immunology. Eli Lilly and Company is listed on the New York Stock Exchange (NYSE) under the ticker symbol LLY" and is considered one of the top pharmaceutical companies in the world. Buying Eli Lilly Stock from Malaysia, Thailand, Indonesia & Vietnam: Investing in Eli Lilly and Company stock can be done by investors from Malaysia, Thailand, Indonesia, and Vietnam through the Zorion investment platform. With Zorion, retail investors can access real US stocks and Pre-IPO companies, allowing them to diversify their portfolios and take advantage of global investment opportunities. To buy Eli Lilly stock from these countries, follow these simple steps: 1. Sign up: Create an account on the Zorion investment platform. Fill in your details accurately to open an investment account. 2. KYC Verification: Complete the Know Your Customer (KYC) verification process by submitting the required identification documents. This step is necessary to comply with regulatory requirements. 3. Deposit Funds: Deposit funds into your Zorion investment account in your local currency. Zorion offers a convenient and secure payment system that accepts multiple payment methods. 4. Research Eli Lilly: Utilize the investment insights and recommendations provided by Zorion to make informed decisions about investing in Eli Lilly stock. Access the educational resources and materials available on the platform to enhance your understanding of the company and its performance. 5. Place an Order: Use the Zorion investment platform to place an order to buy Eli Lilly stock. Enter the desired number of shares you wish to purchase and review the current stock price. 6. Monitor and Manage: After buying Eli Lilly stock, keep track of its performance using the Zorion investment platform. Monitor market trends, track news related to the company, and make informed decisions regarding your investment. Investing in global stocks like Eli Lilly and Company through the Zorion investment platform provides retail investors from Malaysia, Thailand, Indonesia, and Vietnam with an opportunity to diversify their portfolios and tap into the potential growth of the pharmaceutical industry. Start your journey toward building a global investment portfolio through Zorion today."

Eli Lilly and Company Analytics and Performance


LLY: A Company in the LIFE SCIENCES Sector and PHARMACEUTICAL PREPARATIONS Industry

Discover Eli Lilly and Company (LLY), a prominent player in the LIFE SCIENCES sector, specifically within the PHARMACEUTICAL PREPARATIONS industry. As a Common Stock, LLY has a strong presence not only in the United States but also in various countries around the world, including its home base USA.

LLY Financial Performance: Key Ratios and Market Indicators

As of the latest quarter ending 2023-09-30, LLY boasts an EBITDA of 11316300000 and a trailing price-to-earnings ratio (PE ratio) of 128.19. The forward PE ratio stands at 56.5, which indicates stocks potential in earnings. LLY's price-to-sales ratio (TTM) is 20.87, and the price-to-book ratio is 59.65. The company's enterprise value-to-revenue and enterprise value-to-EBITDA ratios are 21.42 and 84.93, respectively.

LLY Stock Stability: Analyzing Marketing Volatility and Trends

LLY stock performance showcases a beta of 0.316, highlighting moderate volatility. The 52-week high and low prices are 742 and 307.17, respectively, with a 50-day moving average of 608.91 and a 200-day moving average of 530.44. With 949307000 shares outstanding, LLY demonstrates strong performance in the market.

LLY Dividends: Current Yields and Shareholder Value

In terms of dividends, Eli Lilly and Company has a dividend per share of 4.37 and a dividend yield of 0.0074. The company's most recent dividend date was 2024-03-08, and the ex-dividend date was 2024-02-14. LLY's financials reveal a book value of 12.48 and earnings per share (EPS) of 5.5, with a diluted EPS (TTM) of 5.5.

LLY Revenue and Profitability: Unveiling the Company's Financial Strength

LLY revenue per share (TTM) is 35.62, and its total revenue (TTM) amounts to 32072499000. The company's gross profit (TTM) is 21911600000. LLY's profit margin stands at 0.155, while the operating margin (TTM) is 0.373. The return on assets (TTM) and return on equity (TTM) are 0.116 and 0.465, respectively.

LLY Growth Prospects: Earnings Growth and Analyst Expectations

LLY has experienced quarterly earnings growth (YOY) of 0.857, but its quarterly revenue growth (YOY) remains stagnant at 0.368. Analysts have set a target price of 645.51 for Eli Lilly and Company stock.

Want To Buy Eli Lilly and Company Stock From Malaysia, Indonesia, Thailand or Philippines? You may also be interested in: